Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac.
Erol Ç, Kuloğlu ZE, Kayaaslan B, Esken G, Altunsoy A, Barlas T, Çınar G, Hasanoğlu İ, Oruç E, İncir S, Azap A, Korkmaz G, Turan Gökçe D, Kırımker OE, Coşkun Yenigün E, Ölçücüoğlu E, Ayvazoğlu Soy E, Çetinkünar S, Kurt Azap Ö, Can F, Haberal M. Erol Ç, et al. Among authors: korkmaz g. Viruses. 2023 Jul 12;15(7):1534. doi: 10.3390/v15071534. Viruses. 2023. PMID: 37515220 Free PMC article.
Are mesenchymal stem cells still effective in acute GvHD management?
Ulu BU, Hindilerden IY, Yigenoglu TN, Tiryaki TO, Erkurt MA, Korkmaz G, Namdaroglu S, Aksoy E, Korkmaz S, Seyhan M, Yilmaz S, Besisik SK, Dal MS, Ulas T, Altuntas F. Ulu BU, et al. Among authors: korkmaz g. Transfus Apher Sci. 2024 Dec 16;64(1):104051. doi: 10.1016/j.transci.2024.104051. Online ahead of print. Transfus Apher Sci. 2024. PMID: 39721135
Effectiveness of ibrutinib in the management of chronic GVHD.
Erkurt MA, Sarici A, Sahin A, Berber I, Korkmaz G, Kuku I, Dal MS, Korkmaz S, Ulas T, Altuntas F. Erkurt MA, et al. Among authors: korkmaz g. Transfus Apher Sci. 2024 Dec 16;64(1):104052. doi: 10.1016/j.transci.2024.104052. Online ahead of print. Transfus Apher Sci. 2024. PMID: 39706127 Review.
Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results.
Dogu MH, Tekgunduz AIE, Deveci B, Korkmaz G, Comert M, Sevindik OG, Yokus O, Serin I. Dogu MH, et al. Among authors: korkmaz g. Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023031. doi: 10.4084/MJHID.2023.031. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37180209 Free PMC article.
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels.
Ceran F, Akıncı S, Uçar MA, Korkmaz G, Gündüz M, Çavdarlı B, Bakanay ŞM, Falay M, Dağdaş S, Dilek İ, Özet G. Ceran F, et al. Among authors: korkmaz g. Turk J Haematol. 2022 Aug 25;39(3):196-203. doi: 10.4274/tjh.galenos.2022.2022-0024. Epub 2022 May 27. Turk J Haematol. 2022. PMID: 35620443 Free PMC article.
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S, Mutlu YG, Malkan ÜY, Mehtap Ö, Keklik Karadağ F, Korkmaz G, Elverdi T, Saydam G, Özet G, Ar MC, Melek E, Maral S, Kaynar L, Sevindik ÖG. Yiğit Kaya S, et al. Among authors: korkmaz g. Leuk Res. 2024 May;140:107495. doi: 10.1016/j.leukres.2024.107495. Epub 2024 Mar 29. Leuk Res. 2024. PMID: 38599153
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S, Dogu MH, Celik S, Ekinci O, Hindilerden IY, Dal MS, Davulcu EA, Tekinalp A, Hindilerden F, Ozcan BG, Hacibekiroglu T, Erkurt MA, Bagci M, Namdaroglu S, Korkmaz G, Bilgir O, Cagliyan GA, Ozturk HBA, Serin I, Tiryaki TO, Ozatli D, Korkmaz S, Ulas T, Eser B, Turgut B, Altuntas F. Akpinar S, et al. Among authors: korkmaz g, korkmaz s. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34629286
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
Pepeler MS, Tıglıoglu M, Dagdas S, Ozhamamcıoglu E, Han U, Albayrak A, Aydın MS, Korkmaz G, Pamukcuoğlu M, Ceran F, Albayrak M, Ozet G. Pepeler MS, et al. Among authors: korkmaz g. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e161-e167. doi: 10.1016/j.clml.2023.12.015. Epub 2024 Jan 17. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38342726
92 results